Date:October 6, 2020 - 1:00 PM to October 6, 2020 - 4:00 PM
- To enhance the understanding on the burden of alcohol use and alcohol-associated liver disease in the United States
- To enhance understanding of the concomitant mental health and substance use disorders among patients with alcohol use and alcohol-associated liver disease
- To bridge the clinical gaps in the alcohol-associated liver disease diagnosis, management and clinical trial design
- To disseminate the NIAAA-sponsored activities on clinical trials and translational research studies to advance the care and treatment of alcohol-associated liver disease to targeted audience
- To provide opportunities for graduate students and post-doctoral fellows to network with expert investigators in the area of alcohol use and alcohol-associated liver disease
- Laura E. Nagy, PhD (nagyL3@ccf.org)
- Suthat Liangpunsakul, MD (firstname.lastname@example.org)
- Lorenzo Leggio, MD, PhD (email@example.com)
- Svetlana Radaeva, PhD (firstname.lastname@example.org)
Tuesday, Oct 6, 2020 1:00 pm | 2 hours 30 minutes | (UTC-04:00) Eastern Time (US & Canada)
Meeting number: 126 760 8475
Join by phone
1-650-479-3208 Call-in toll number (US/Canada)
Access code: 126 760 8475
Moderators: Laura E Nagy, PhD, Cleveland Clinic and Suthat Liangpunsakul, MD, Indiana University, IN
Format: 30 min per speaker (~22 min presentation and 8 min Q&A)
|George Koob, PhD, NIAAA Director
||Pathogenesis and mechanism of alcohol-associated liver disease – pave the way to therapeutic targets
Inflammation or impaired regeneration: which pathways are important for treatment?
|Anna Mae Diehl, MD
||From bench to bedside - Disease Definitions and clinical studies AH
Clinical trials in patients with AH – based on disease severity – inclusion and exclusion criteria, endpoints, duration, and confounders.
|Mack Mitchell, MD
||Clinical studies and the use of biomarkers in the real world, obstacles and challenge: Insights from the design and implementation of medications development trials for alcohol use disorder.
||Mark Thursz, MD
|Clinical Addiction perspective –
How to address AUD and substance abuse disorder in patients with alcohol-associated liver disease: behavioral and pharmacological intervention?
|Lorenzo Leggio, MD, PhD
||Liver transplantation in patients with alcohol-associated liver disease
Preventing relapse after liver transplant: “app” based support.
|Betsy McCaul, PhD